Skip to content
Company Terminals Nifty 50 Company TerminalsNifty 500 Index TerminalRecently Listed IPOs Markets Bhav Dhan Index: fear and greed, decodedFII DII data today, decodedNifty P/E, measured five waysMorning Open: before the bellEvening Close: the day, readThis season's results, read forensicallyAlerts by email and TelegramMarket Movers: why stocks moved IPO Intel Live and upcoming IPOsRecently listed: score vs outcomeSME IPO forensics Research Research and analysisIndustry research Calculators All calculatorsGold desk Services Roadmap Pricing Get started →
The $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focusThe $13 Billion Machine: Inside the Macro-Economics of the 2026 FIFA World CupAlibaba share price is up 16% today. what next for Baba stock?IPO Allotment status check online by PAN number 2025UnitedHealth (UNH Stock): You should stay away from itQ4 results live updates: Adani Group companies in focus
NSE: IPCALABISIN INE571A01038

Ipca Laboratories Ltd.

HealthcareNifty 500Statement-builtBalanced risk
₹1,845.50
−67.60 (−3.53%)
Close 2026-10-16
52-week range
₹1,269−8.2% from high₹2,010
Last 6 months +25.7%
Trend
vs 50-DMA −2.9%vs 200-DMA +8.3%Volatility 30%
Analyst view from the market data feed
25% bullish
16 analystsmean rating 2.00
Price
₹1,845.50
Mkt cap
₹46,667 cr
P/E (TTM)
33.0xexcl. exceptional items
P/B
6.02x
Book value
₹318.9
ROE
12.2%
Op margin
16.8%
Net margin
13.6%
D/E
0.10
Div yield
0.31%
Q2 FY27 resultsClean on 15 checksHide
Revenue₹2,910 cr▲ 13.8%on the year▲ 4.4%on the quarter
EBITDA₹673 cr▲ 23.6%on the yearmargin 23.1% (+183 bps)
Net profit₹389 cr▲ 38.8%on the year▼ 8.2%on the quarter
EPS₹14.79▲ 32.8%on the year
  1. Revenue ₹2,910 cr, +13.8% on the year (this quarter has averaged +12.2% over the last 2 years); EBITDA margin 23.1%, +183 bps.
  2. Core profit grew faster than reported profit: core +63.0%, reported +38.8%. Other income, exceptional items or tax held the headline back.
  3. Every check that could run (15 of 19) came back quiet.
✓Core profit grew faster than reported profit: one-offs held…
Management said
  • Indian formulations income up 14% at Rs 1157.20 crores.press release
  • Exports Income up 17% at Rs. 951.39 crores.press release
  • Consolidated Net Profit at Rs. 375.13 crores (after exceptional items) up 33%.press release
Market today: Funded rallyBhav 58 · Dhan 70 · 6 NovBhav Dhan Index →
Consolidatedstandalone figures are read separately and never mixed into these tables
What this company actually does

A plain-language read of the business, how it actually earns, where the edge is, and the economics of every reported segment — taken from the annual report and investor presentation, not a one-line industry label.

  • Business model in plain language
  • The revenue engine — what actually generates cash
  • Segment revenue, PBIT, margin and capital employed
  • Operating KPIs — volumes, capacity, utilisation
Live once this company's filings, calls and disclosures have been read.

What's newsince the last filing we processed

Annual report Annual Report 2026 Open
Earnings call Nov 2025 Open

Price in context split-adjusted

1M−5.4%
6M+25.6%
1Y+43.2%43.2% a year
From high−8.2%worst -11%
vs Nifty, 1Y+45.4 ptsNifty −2.2%
Beta0.00vs Nifty 50
Volatility30%a year

Trading at 36.7x earnings against its own median of 36.5x: 0.0 standard deviations above its usual range. This compares the company with its own history, not with other companies.

How to read this: Price shows the closing price with its 50-day (amber) and 200-day (grey) averages; bars at the bottom are daily volume, green on up days and red on down days; dashed lines mark the 52-week high and low. vs Nifty 50 starts both at 100 so you can see which did better over the period. P/E shows what the market paid for each rupee of profit, inside the band it usually trades in. Drawdown shows how far below its best price the share has been. Hover anywhere for the numbers on that day.

What you must understand

The three to six things that actually matter about this company, each with the exact filing and note it came from — never a fact without the context that makes it meaningful.

  • Reported profit vs operating profit
  • Management narrative vs the numbers
  • Standalone vs consolidated divergence
  • Audit opinion vs headline optimism
Live once this company's filings, calls and disclosures have been read.

Reading the Statements forensic interpretation

What the numbers mean when read together — computed from the filings, not a score.

Capital work-in-progress is sticky

Capital work-in-progress has stayed high (17% of fixed assets) without converting to productive assets — worth checking whether projects are genuinely progressing.

Why this reading: Noted with caution — worth watching, but not yet conclusive on its own. Business has ups and downs; one soft reading is not a verdict.

Full read

CWIP ₹773 cr vs ₹343 cr two years earlier, against fixed assets ₹4,627 cr. Perennial CWIP that never becomes a fixed asset can hide stalled projects or capitalised costs that should have been expensed.

Operating cash flow backs the profit

Operating cash is 96% of trailing profit — the earnings are converting to real cash, not just accruals.

Why this reading: A positive signal: cash conversion at or above ~0.9 means reported profit is showing up as actual cash.

Full read

Operating cash ₹1,142 cr against trailing net profit ₹1,184 cr. Consistent conversion near or above 1.0 is a hallmark of genuine earnings.

Profit growing with revenue

Both revenue and profit grew over the last year (10.6% and 68%) — growth is translating to the bottom line.

Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.

Full read

Trailing revenue ₹10,124 cr, trailing profit ₹1,376 cr. Profit growing at least as fast as revenue indicates operating leverage or pricing power.

Generates free cash

Free cash flow is positive and consistent — the business funds itself after capex.

Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.

Full read

Latest free cash flow ₹486 cr. Negative in only 1 of 12 years. A self-funding business needs less external capital and dilutes less.

Deleveraging

Borrowings have fallen 44% over two years — the balance sheet is getting lighter.

Why this reading: A positive signal in the numbers, shown for balance alongside the concerns.

Full read

Borrowings down to ₹809 cr from ₹1,438 cr. Falling debt reduces finance cost and financial risk.

Forensic modelscomputed from the filed statements

Every score below is calculated here from the reported numbers — none of it is asserted. Open the notebook at the foot of the section to see each formula with this company's figures in it.

Altman Z″

Needs current assets and current liabilities.

Piotroski F

7 / 8 1 not testable
  • Profitable this year
  • Operating cash positive
  • Return on assets improved
  • Cash exceeds profit
  • Leverage reduced
  • Liquidity improved
  • No share dilution
  • Margin improved
  • Assets working harder
What is this, and how do I read it?

Piotroski F-Score — fundamental momentum — Joseph Piotroski, University of Chicago, 2000, in a study of whether accounting signals could improve returns among cheap stocks.

Nine yes-or-no tests across profitability, leverage and operating efficiency. Each pass scores one. It asks a narrow question: is this business getting better or worse on its own terms, year over year?

Profitability (4 tests)
Positive profit, positive operating cash, improving return on assets, and cash exceeding profit. The last is the quality test — profit that outruns cash is the one to question.
Leverage and liquidity (3 tests)
Falling debt, improving current ratio, no new shares issued. Growth funded by dilution scores zero here.
Operating efficiency (2 tests)
Improving margin and improving asset turnover.

How to read it7 or more suggests improving fundamentals; 3 or fewer suggests deterioration. It measures direction, not quality — a weak company improving can score higher than a strong one holding steady.

Where it failsA single year of comparison, so one unusual year distorts it. Says nothing about valuation, competitive position or management. Piotroski designed it to rank already-cheap stocks, not to judge a company in isolation.

Beneish M

Needs trade receivables, current assets, other expenses.

Cash vs profit

1.32× 12-year cumulative

Accruals are 0.3% of assets. Free cash flow negative in 1 of 12 years.

DuPont — return on equity FY2026

Net margin12.3%× Asset turnover0.78×× Leverage1.53×= ROE14.7%
What is this, and how do I read it?

DuPont decomposition — Devised inside the DuPont Corporation in the 1920s and still the standard way to read a return on equity.

Splits return on equity into its three sources, so the same headline number can be traced to very different businesses.

Net margin
What the company keeps from each rupee of sales. High margin points to pricing power or a genuine cost advantage.
Asset turnover
Sales generated per rupee of assets. High turnover points to efficiency — a retailer earns this way, a utility never will.
Leverage (equity multiplier)
Assets divided by equity. This multiplies whatever the first two produce, in both directions.

How to read itA 20% ROE built on margin and turnover is a different proposition from a 20% ROE built on 3× leverage. The first survives a downturn; the second amplifies it.

Where it failsA single year. Negative equity makes it meaningless. Leverage is structural for lenders, so the third term carries no signal there.

Leverage & coverage FY2026

Debt / equity0.10×
Interest coverage20.91×
ROCE17.0%

Capital that builds FY2023 → FY2026

Capital deployed+87%
Revenue produced+55%
Still in CWIP₹773 cr

Capital and revenue are growing at broadly similar rates — the asset base is being used, not just added to.

The formula notebook — every number above, worked out
Cash vs profit cumulative operating cash flow ÷ cumulative net profit ₹9,031 cr ÷ ₹6,829 cr, over 12 years 1.32× Above 1.0 means cash exceeds reported profit — the healthier reading.
Accruals (Sloan) (net profit − operating cash flow) ÷ average total assets (₹1,184 − ₹1,142) cr ÷ average assets 0.3% The share of profit that is accounting entries rather than cash. Above ~10% is where accruals start to dominate.
DuPont — return on equity net margin × asset turnover × leverage 12.3% × 0.78 × 1.53 14.7% Splits ROE into whether returns come from operations or from borrowing.
Interest coverage EBIT ÷ finance cost ₹1,652 cr ÷ ₹79 cr 20.91× How many times operating profit covers the interest bill.
Debt to equity borrowings ÷ net worth ₹809 cr ÷ ₹8,063 cr 0.10× Read against the sector — infrastructure carries more than software.
Capital that builds growth in fixed assets + CWIP, against growth in revenue capital +87% vs revenue +55%, FY2023 to FY2026 32pp gap Money going in far faster than revenue coming out. For an incubator this is expected — the test is whether it eventually converts.

Going deepersame statements, harder questions

Montier C-Score

Needs more balance-sheet detail (only 3 of 6 flags testable).

Return on invested capital FY2026

ROIC14.0%
On new capital since FY2023 41.6%
Capital employed₹8,872 cr

NOPAT over equity plus debt less cash, at a notional 25% tax. Incremental ROIC is the return on money put in since then — the number that decides whether growth creates value or consumes it.

What is this, and how do I read it?

Return on invested capital, and incremental ROIC — Standard in corporate finance; the incremental form was popularised by Michael Mauboussin as the test of whether growth creates value.

ROIC measures what the business earns on all the capital it employs — equity plus debt, less cash. Incremental ROIC asks a sharper question: what has it earned on the money put in since a chosen year?

NOPAT
Operating profit after a notional tax charge, so the figure is independent of how the company is financed. We use 25%.
Invested capital
Equity plus borrowings less cash — the money actually at work.
Incremental ROIC
Change in NOPAT divided by change in invested capital. If it sits below the cost of capital, growth is destroying value however fast revenue rises.

How to read itROIC comfortably above the cost of capital — call it 11–13% in India — means growth compounds. Below it, growth consumes. Incremental below headline means recent investment is earning less than the legacy business.

Where it failsDistorted in the year of a large acquisition. Understated for companies mid-build, where capital is deployed but capacity has not yet been commissioned — an incubator will look poor until it does not.

Earnings quality ladder FY2026

Cash ÷ EBITDA0.57×
Cash ÷ profit0.96×
Free cash ÷ profit0.41×

Read downward. Cash can cover EBITDA and still not survive capex — the third rung is where a capital-hungry business shows itself.

What is this, and how do I read it?

The earnings quality ladder — Not a named model — the standard sequence an analyst walks when testing whether reported profit is real.

Three ratios read in order, each stricter than the last.

Cash ÷ EBITDA
Does operating profit arrive as cash? Below 0.8 points to working capital absorbing it.
Cash ÷ profit
Does bottom-line profit arrive as cash? Below 1.0 persistently is the classic warning.
Free cash ÷ profit
Does anything survive capex? This is where capital-hungry businesses reveal themselves — a company can pass the first two and still never generate spendable cash.

How to read itRead downward. Each rung failing where the one above passed tells you exactly where the cash is going.

Where it failsA single year of heavy capex depresses the third rung legitimately. Judge it across a cycle.

What the price implies

30.9% free cash flow growth, every year for ten years

The growth rate that makes today's market value equal the discounted cash flows, at a 11.5% discount rate and 4.0% terminal growth. Not a forecast — the arithmetic of what is already in the price. Compare it with what the business has actually delivered.

What is this, and how do I read it?

Reverse DCF — the growth already in the price — A standard inversion of discounted cash flow, used to avoid the forecasting problem entirely.

Instead of forecasting cash flows and deriving a value, it takes today's market value as given and solves for the growth rate that would justify it. The output is not a view — it is the arithmetic of what the market is currently assuming.

Discount rate
The return required for the risk taken. We use 11.5%, roughly the long-run cost of equity in India.
Terminal growth
Growth beyond the explicit ten years. We use 4%, near long-run nominal GDP.
The output
The free-cash-flow growth rate, every year for a decade, that makes the discounted total equal today's market value.

How to read itCompare it with what the business has actually delivered. A price implying 30% a year against a decade of 15% is a demanding assumption; the reverse is a modest one.

Where it failsUseless when free cash flow is negative or unusually depressed, which is common mid-capex. Highly sensitive to the discount rate — a point either way moves the answer materially.

Cost of debt FY2026

Interest ÷ average borrowings7.27%
Average borrowings₹1,086 cr

Against a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%.

What is this, and how do I read it?

Cost of debt — Interest expense over average borrowings — the effective rate the company actually pays.

What the lenders charge, which is a market verdict on credit quality that no rating agency delay affects.

Well below the policy rate
Suggests interest is being capitalised into assets rather than expensed, or that funding comes from related parties on non-market terms.
Near the policy rate plus a normal spread
Ordinary bank funding. Nothing to explain.
Well above
Lenders are pricing risk the equity market may not yet be.

How to read itAgainst a policy rate near 6%, most sound Indian corporates borrow between 7% and 10%. Read the direction over years as much as the level.

Where it failsUnderstated where a large share of interest is capitalised into projects under construction. Not meaningful for lenders, where interest is cost of goods.

Reading the numbers on this pagetwo bases, both shown

Some figures appear twice on this page with different values. That is not an error — they sit on different bases. The live feed reports a rolling twelve months; everything computed here comes from the last audited statements. Both are shown so you can see which is which.

Operating margin
Trailing twelve months, live feed16.8%
FY2026, as filed20.7%
4.0% apart

Where the two disagree, every model, screen and ratio computed on this page uses the filed figure, because the rest of the page is on that basis.

What the filings we hold do not give

Models that need these lines are withheld rather than estimated: net worth, current assets, current liabilities, trade receivables, inventory, net block. Nothing on this page is back-solved from a figure the company did not publish.

Published screening frameworksrules applied, not opinions quoted

Each framework below is a set of stated, mechanical criteria from published work, run against this company's own filed numbers. Passing or failing a screen is not a verdict — different frameworks disagree by design, and that disagreement is itself informative.

Graham — defensive investor

3 / 5
  • Debt below net worth ₹809 cr vs ₹8,063 cr
  • Positive earnings every year 12 of 12 years
  • Earnings growth over the period 33% since FY2022
  • P/E below 15 33.0×
  • P/E × P/B below 22.5 198.4

Benjamin Graham's stated criteria for a defensive stock, applied to the filed numbers. A company failing several is not disqualified — Graham designed these to be deliberately strict.

Greenblatt — magic formula

0 / 2
  • Return on capital above 20% 18.6%
  • Earnings yield above 8% 3.0%

Two ratios only: what the business earns on its capital, and what you pay for those earnings. Designed to be ranked across a universe rather than read in isolation.

O'Neil — CAN SLIM growth tests

2 / 4
  • Annual earnings growth above 25% 55%
  • Revenue growth above 20% 8%
  • Return on equity above 17% 14.7%
  • Share count not expanding equity capital ₹25 cr

The fundamental half of William O'Neil's framework. The market and leadership components are judgement calls and are not scored here.

Quality — compounder tests

4 / 4
  • Cash conversion above 0.9× 1.32× over 12 years
  • ROCE above 15% 17.0%
  • Interest covered more than 4× 20.91×
  • Debt below half of equity 0.10×

The characteristics long-term holders commonly look for: cash-backed earnings, high returns on capital, and debt that never forces a decision.

Against the sector48 companies

Median of the companies we hold in the same sector (Healthcare). Every figure on both sides is the live feed's trailing twelve months, so the two are measured the same way whatever depth of extraction this company has had. A number only means something next to something else — expensive against the market and cheap against peers are different facts.

P/E
33.0×
47.9×
-31%
P/B
6.0×
6.3×
-4%
Return on equity
12.2%
17.5%
-30%
Operating margin
16.8%
19.1%
-12%
Net margin
13.6%
15.7%
-13%
Dividend yield
0.3%
0.3%
-3%
this companysector median

The page in pictures

Revenue and what it leaves behind

Bars are revenue; the line is net margin. Revenue rising while the line falls is the shape worth noticing.

FY19 · 3,746FY19FY20 · 4,619FY20FY21 · 5,395FY21FY22 · 5,797FY22FY23 · 6,204FY23FY24 · 7,662FY24FY25 · 8,897FY25FY26 · 9,599FY26
Revenue (₹ cr)Net margin %

Where the year's cash went — FY2026

Operating cash first, then what the business spent and raised.

1,142Operating cash−247Investing−754Financing

Quality over time

One year is a snapshot. These are the two lines that matter across a cycle.

3.42.51.60.7FY19FY20FY21FY22FY23FY24FY25FY26
Cash ÷ profit (×)ROCE (÷10)

Where cash gets stuck

Rising debtor or inventory days against flat sales is the earliest visible sign of stress.

38926614219FY19FY20FY21FY22FY23FY24FY25FY26
Debtor daysInventory daysPayable daysCash cycle
Growth & valuation workspace

Set your own assumptions and watch the numbers move. A scenario calculator — the outputs are the arithmetic of your inputs.

User-driven scenario tool. Implied value and CAGR follow only from the assumptions you set — not a FinMinutes forecast, recommendation, or target price.

Valuation & quality

One canonical set of figures — the same numbers used everywhere else on this page and on the screener.

What you payHow the price compares with earnings, book and sales.
P/E (TTM)
33.0x
trailing 12m, live feed
P/B
6.02x
P/S
4.79x
PEG
1.08
Dividend yield
0.31%
What it earnsMargins and returns as the live feed reports them, on a rolling twelve months. The models above compute the same measures from the last audited statements, so the two can differ.
Operating margin
16.8%
trailing 12m, live feed
Net margin
13.6%
trailing 12m, live feed
Return on equity
12.2%
trailing 12m, live feed
How it is fundedLeverage and what is returned to shareholders.
Debt / equity
0.10
conservative
Payout ratio
11.6%
Book value / share
₹318.9
Return on equity of 12.2% is built on a 13.6% net margin and debt of 0.10x equity. The full DuPont breakdown sits in the forensic models above.

Ownership & Skin in the Game

How the register has moved over recent quarters — the direction matters more than the level.

Promoter ― 0.00
Dec '2544.72% Mar '2644.72% Jun '2644.72% Sep '2644.72%

Promoter held steady from 44.72% to 44.72% across these quarters.

FII ▲ 0.90
Dec '2510.62% Mar '2610.63% Jun '2610.72% Sep '2611.52%

FII rose from 10.62% to 11.52% across these quarters.

MF ▲ 0.55
Dec '2530.52% Mar '2631.24% Jun '2631.15% Sep '2631.07%

MF rose from 30.52% to 31.07% across these quarters.

Other ▼ 1.45
Dec '2514.14% Mar '2613.41% Jun '2613.41% Sep '2612.69%

Other trimmed from 14.14% to 12.69% across these quarters.

Working capital12-year series

Where cash gets stuck. A rising inventory or debtor line against flat sales is the earliest sign of trouble in the numbers.

MeasureFY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Debtor days
How long customers take to pay
6671555758807777
Inventory days
How long stock sits before it sells
316294337337276350336353
Payable days
How long the company takes to pay suppliers
15413514010183110111122
Cash conversion cycle
Debtor + inventory − payable days
228229251293251321302308
Working capital days888810310271111101109
ROCE %
Return on capital employed
16.0%19.0%31.0%20.0%11.0%13.0%15.0%17.0%

Pharma vitalsthe numbers this business is run on

Quarter by quarter

MetricQ2 FY27Q1 FY27Q2 FY26
India growth YoY14%—1,019%
Gross margin72.03%71.5%75.36%
Exports Income (₹ crore)951.39—813.65
Generics Export Formulations Revenue (₹ crore)364.48—268.01

From the quarterly results and the earnings call, read by FinMinutes. Latest quarter, read in full.

Read using the Pharmaceuticals framework (named in the filing read). Primary valuation lens: P/E excluding one-time exclusivity gains.

Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.

Trends

The shape of the business over time (annual) — read the direction, not the single print.

Revenue (₹ cr)
FY20215.4kFY20225.8kFY20236.2kFY20247.7kFY20258.9kFY20269.6k
Net profit (₹ cr)
FY20211.1kFY2022890FY2023479FY2024523FY2025785FY20261.2k

Annual Profit & Loss ₹ cr

LineFY2021FY2022FY2023FY2024FY2025FY2026
Revenue from operations5,3955,7976,2047,6628,8979,599
Other income595412317-11480
Depreciation209232262357398418
Finance cost1211481418879
Profit before tax1,3891,1367458431,1311,573
Net profit (owners)1,1418904795237851,184
EPS (₹)44.9434.8518.5821.5729.0844.98

Exceptional items, total income and EBITDA are read from the filed statements.

Quarterly Financials ₹ cr

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue2,0342,0532,0332,0932,3552,2452,2472,3092,5562,3922,3882,788
Other Income-191-118212620-17933-30384825
Expenses1,6731,7221,7111,7001,9131,7821,8181,8922,0121,8591,9052,119
Depreciation90100989910098100100103108107111
Finance cost443329242317221920182012
Profit before tax22528977290345368128331392446404572
Net Profit136221119924627664233281364307424
EPS5.727.092.357.589.059.782.679.1911.1412.8611.7915.84

Balance Sheet ₹ cr, annual

ItemFY2021FY2022FY2023FY2024FY2025FY2026
Equity Capital252525252525
Reserves4,6765,4675,8176,3076,9238,038
Borrowings2658071,4811,4381,363809
Net block2,0722,4182,7514,5544,2674,627
CWIP235306140343622773
Investments505989626862980844
Total Assets6,0667,6378,62311,09711,74412,350

Cash Flow ₹ cr

LineFY2021FY2022FY2023FY2024FY2025FY2026
Cash from operations1,0908568069451,3211,142
Cash from investing-521-851-725-1,215-870-247
Cash from financing-306427507-553-283-754
Free cash flow731380347543551486
Net change in cash264432588-823169142

Cash from operations is the number profit has to answer to. Free cash flow is what remains after the business pays for its own growth.

From the filings, calls & disclosures

The part no one reads: the auditor's opinion, the contingent liabilities buried in the notes, the covenants, and the claims in the deck placed beside the figures that test them.

  • Buried in the footnotes — what the notes disclose and the summary does not
  • Risk register — every dispute, probe and contingent liability with its amount
  • Audit & governance — opinion type, emphasis of matter, going concern, subsidiary coverage
  • Guidance & forward view
  • Narrative vs numbers
  • Segment intelligence
Live once this company's filings, calls and disclosures have been read.
The analyst grilling

Where analysts pressed management on the earnings call, and exactly how management answered — the questions that were hardest to answer are usually the ones that matter.

  • The question, and who asked it
  • Management's answer, in their own framing
Live once this company's filings, calls and disclosures have been read.

Disclosure & evidencewhat the filings actually show

These are coverage counts, not ratings. Each one asks a fixed set of questions of the filings and reports how many the company answered. A company that discloses nothing counts nothing here — that is a statement about the disclosure, not about the business.

Capital discipline

4 of 4 disclosed weighted 10 of 10
What was looked for
  • Profit converts to cash — 1.32× over 12 years
  • Free cash flow not persistently negative — 1 of 12 years negative
  • Capital converts into revenue — capital +87% vs revenue +55%
  • Interest comfortably covered — 20.91×

Others in Healthcare

The same read, applied to the companies this one competes with.

Results · Q2 FY27July to September 2026

Open the full results page ↗
✓Clean on 15 checks✓1 positive15 of 19 checks ran · read from the filing
Revenue₹2,910 cr▲ 13.8%on the year▲ 4.4%on the quarter
EBITDA₹673 cr▲ 23.6%on the yearmargin 23.1% (+183 bps)
Net profit₹389 cr▲ 38.8%on the year▼ 8.2%on the quarter
EPS₹14.79▲ 32.8%on the year

What changed

  1. Revenue ₹2,910 cr, +13.8% on the year (this quarter has averaged +12.2% over the last 2 years); EBITDA margin 23.1%, +183 bps.
  2. Core profit grew faster than reported profit: core +63.0%, reported +38.8%. Other income, exceptional items or tax held the headline back.
  3. Every check that could run (15 of 19) came back quiet.

The quarter, explainedfrom the filing and the statements

Ipca Laboratories Ltd. reported revenue of ₹2,910 cr for July to September 2026, +13.8% on the year and +4.4% on the quarter. That is in line with how this quarter has grown in recent years (+12.2% on average). It is the highest quarterly revenue in the last 12 quarters on record. Over the last four quarters revenue comes to ₹10,478 cr, +12.0% on the four before.

Operating profit (EBITDA) was ₹673 cr, a margin of 23.1%, +183 bps on the year and −87 bps on the quarter. Over the last 8 quarters the margin has ranged from 18.0% to 24.0%, averaging 21.1%. Operating costs grew +11.2% against revenue growth of +13.8%, so more of each rupee of sales reached operating profit.

Net profit was ₹389 cr, +38.8% on the year and −8.2% on the quarter, with earnings per share of ₹14.79. Profit before other income, one-offs and tax grew faster, at +63.0%; other income, one-offs or tax held the headline back. The tax rate of 28% is in line with its recent average. Profit over the last four quarters totals ₹1,485 cr, +73.9% on the four before.

Of the 13 companies in Pharmaceuticals that have reported Q2 FY27 so far, Ipca Laboratories Ltd. ranks 6th on revenue growth; the sector median is +11.8%. Its margin moved +183 bps on the year against a sector median of −60 bps.

Pharma quarters swing with US generic launches and price erosion, while India formulations grow more steadily. Currency gains and other income can be material, so headline profit needs a check against operating profit.

On earnings per share of ₹55.28 over the last four quarters, the stock at ₹1,845.50 trades at 33.4 times trailing earnings.

Questions to ask: none this quartereach one with its numbers and source

No check fired. That is a statement about the checks below, not a verdict on the company.

Also worth knowing

✓Positive

Core profit grew faster than reported profit: one-offs held the headline down.

Reported profit +38.8% on the year; profit before other income, exceptional items and tax +63.0%.

Source: Results filing

Could not run on this quarter: IPO money used as stated, Related-party transactions, Promoter pledges and allotments, Earlier promises against delivery. The filing did not carry these lines.

Where the profit change came fromSep '25 → Sep '26

₹281 crSep'25+₹129 crBusiness(EBITDA)−₹11.2 crDepreciation+₹7.0 crFinancecost−₹2.8 crOtherincome−₹34.0 crExceptionalitems−₹47.6 crTax+₹68.7 crOtherlines₹389 crSep'26Scale starts at ₹203 cr, not zero, so the changes are visible

Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.

The half year: balance sheet and cashfiled with Q2

Balance sheetSep '26Last year endChange
Trade receivables₹2,395 cr₹2,014 cr▲ 18.9%
Inventory₹2,938 cr₹2,731 cr▲ 7.6%
Cash₹207 cr₹437 cr▼ 52.6%
Bank balances₹58.3 cr₹127 cr▼ 54.3%
Long-term borrowings₹67.4 cr₹109 cr▼ 38.3%
Short-term borrowings₹559 cr₹595 cr▼ 6.0%
Trade payables₹1,074 cr₹940 cr▲ 14.3%
Net block₹4,282 cr₹4,180 cr▲ 2.4%
Capital work in progress₹832 cr₹762 cr▲ 9.2%
Equity₹8,678 cr₹8,064 cr▲ 7.6%
Total assets₹13,133 cr₹12,370 cr▲ 6.2%
Cash flow, year to dateThis yearLast year
Operating cash flow₹573 cr₹780 cr
Capital expenditure−₹443 cr−₹461 cr
Investing cash flow−₹341 cr−₹298 cr
Financing cash flow−₹252 cr−₹211 cr
Dividends paid−₹154 cr−₹52.7 cr

Operating cash flow was 0.70× profit. Receivables at 77 days of sales (+0 days against the last year end). Inventory at 94 days of sales (−9 days).

From the filingauditor, IPO money, related parties, promoters

✓Auditor's reviewUnmodified conclusion · N V C & Associates LLP

Other matter 1: “

We did not review the special purpose consolidated financial results of one subsidiary, whose consolidated financial results reflect total assets of Rs. 3905.28 Crores, total revenue of Rs. 1303.82 Crores and net profit after tax of Rs. 61.13 Crores and… Read in fullWe did not review the special purpose consolidated financial results of one subsidiary, whose consolidated financial results reflect total assets of Rs. 3905.28 Crores, total revenue of Rs. 1303.82 Crores and net profit after tax of Rs. 61.13 Crores and total comprehensive income of Rs 61.27 Crores for the half year ended September 30, 2026, before giving effect to elimination of intra-group transactions as considered in the preparation of the consolidated financial results. These special purpose financial statements have been prepared for the purposes of harmonizing accounting policy as followed by parent company for inventory valuation i.e. change the cost formula followed by the subsidiary company from weighted average to First in First out and have been reviewed by other auditors whose report has been furnished to us by the Management and Our conclusion on the statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter.
”

Other matter 2: “

These consolidated financial results also include the Group's share of loss after tax of Rs 2.54 crores and Total Comprehensive loss of Rs 2.54 crores in respect of one associate and one joint venture, for the half year ended September… Read in fullThese consolidated financial results also include the Group's share of loss after tax of Rs 2.54 crores and Total Comprehensive loss of Rs 2.54 crores in respect of one associate and one joint venture, for the half year ended September 30, 2026, as considered in the Statement. These unaudited financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associates and joint venture, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matters.
”

Other matter 3: “

We also did not review the financial results of ten subsidiaries whose financial results reflects, total assets Rs. 1,263.94 crores total revenues Rs. 259.23 Crores, net profit after tax of Rs 4.56 Crores and Total Comprehensive loss of Rs 9.11… Read in fullWe also did not review the financial results of ten subsidiaries whose financial results reflects, total assets Rs. 1,263.94 crores total revenues Rs. 259.23 Crores, net profit after tax of Rs 4.56 Crores and Total Comprehensive loss of Rs 9.11 crores for the half year ended September 30, 2026, as considered in these financial results. The consolidated financial results also include the Group's share of net profit of Rs 1.78 crores and Total Comprehensive income of Rs 1.78 crores in respect of 1 joint ventures. These financial statements of immaterial subsidiaries and joint venture have been prepared by the management for consolidation purposes and are incorporated in these consolidated financial statements on the basis of the management accounts on which we have not carried out any review procedures. Our conclusion is not modified on this account.
”

Filing p. consolidated limited review report p.1-3

?Governance eventsOther

Board of Directors approved the scheme of amalgamation of M/s. Krebs Biochemicals & Industries Ltd. with the Company w.e.f. April 1, 2026, subject to necessary consents and approvals. (p. consolidated note 6)

Inside the profitother income, one-offs, tax

Other income, line by line

  • Interest Income (6M consolidated): 19.46 crore (recurring)consolidated cash flow statement
  • Net gain on financial assets through FVTPL (6M consolidated): 2.12 crore (recurring)consolidated cash flow statement
  • Profit on sale of Property, plant & equipment (6M consolidated): 3.88 crore (recurring)consolidated cash flow statement

One-offs

  • Provision for legal claims by Laboratories Servier against Niche Generics / Unichem (£1.9 million): 24.26 crore. Seen before: noconsolidated note 4(d)

Tax: Consolidated tax expense of ₹155.63 crore (current tax ₹147.35 crore, deferred tax charge ₹8.28 crore) on Profit before tax of ₹547.17 crore for Q2 FY27

Pharma vitalsthe numbers this business is run on

MetricQ2 FY27Q1 FY27Q2 FY26
India growth YoY14%—1,019%
Gross margin72.03%71.5%75.36%
Exports Income (₹ crore)951.39—813.65
Generics Export Formulations Revenue (₹ crore)364.48—268.01

Worked out from filed numbers. Gross Margin: Consolidated Gross Margin = (Revenue ₹2,909.94 crore - Cost of materials/purchases/inventory change ₹813.96 crore) / ₹2,909.94 crore * 100

Checks this sector needs

iStatus of each US-filed plant

Plant-wise regulatory status is not explicitly updated in the quarterly financial release notes; operations span vertically integrated FDF and API facilities across India.

Facility-specific regulatory audit updates were omitted from the quarterly results presentation.

✓Price erosion stated

Exports income expanded 17% YoY to ₹951.39 crore in Q2 FY27, with Generics export formulation revenue growing 36% YoY to ₹364.48 crore, absorbing base generic pricing pressure.

Volume-driven generic export growth (+36% YoY) effectively offset US/EU price erosion.

✓One-product dependence

Revenue stream is well-balanced between Domestic Formulations (₹1,157.20 crore), Export Formulations (Branded ₹172.50 crore, Institutional ₹115.76 crore, Generics ₹364.48 crore), Domestic APIs (₹135.56 crore), and Export APIs (₹298.65 crore).

Diversified therapeutic and product mix across formulation markets and active pharmaceutical ingredients mitigates product concentration risk.

Read using the Pharmaceuticals framework (named in the filing read). Primary valuation lens: P/E excluding one-time exclusivity gains.

Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.

What management saidquoted, with source

  • Indian formulations income up 14% at Rs 1157.20 crores.press release, release p.1
  • Exports Income up 17% at Rs. 951.39 crores.press release, release p.1
  • Consolidated Net Profit at Rs. 375.13 crores (after exceptional items) up 33%.press release, release p.1
  • Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 22.97% in Q2 FY27 as against @ 21.68% in Q2 FY26.press release, release p.1

Guidance given this quarter

MetricGuidanceForAgainst earlier guidance
Amalgamation of Krebs Biochemicals & Industries Ltd.Approved w.e.f. April 1, 2026FY2026-27unchanged or first given

Held for next quarter's said-then-did check.

Segments

SegmentRevenueYoYResultYoY
Pharmaceuticals₹2,910 cr▲ 13.8%₹571 cr▲ 27.0%

Every quartersame rules, every quarter

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27Q2 FY27
Revenue₹2,053 cr₹2,033 cr₹2,093 cr₹2,355 cr₹2,245 cr₹2,247 cr₹2,309 cr₹2,557 cr₹2,392 cr₹2,388 cr₹2,788 cr₹2,910 cr
YoY——+32%+16%+9%+11%+10%+9%+7%+6%+21%+14%
EBITDA margin16.1%15.8%18.8%18.7%20.6%19.1%18.0%21.3%22.3%20.3%24.0%23.1%
Other income, % of PBT31%−153%7%8%5%−140%10%7%9%12%4%5%
Exceptional items———————₹58.3 cr———₹24.3 cr
Tax rate23%—31%29%25%49%29%28%18%24%26%28%
Net profit₹221 cr₹1.0 cr₹199 cr₹246 cr₹276 cr₹64.0 cr₹233 cr₹281 cr₹364 cr₹307 cr₹424 cr₹389 cr
YoY——+21%+81%+25%+6,300%+17%+14%+32%+380%+82%+39%
Core profit YoY——+30%+41%+76%+57%+11%−4%+17%+16%+83%+63%
EPS₹7.09₹2.35₹7.58₹9.05₹9.78₹2.67₹9.19₹11.14₹12.86₹11.79₹15.84₹14.79
Flags2·✓1✓1✓111✓✓

Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.

DISCLAIMER: FinMinutes is a financial data and analytics platform, not a registered investment adviser. Everything here is for educational and informational purposes. Forensic interpretations are computed from disclosed data and are not recommendations. Do your own due diligence.
Chat on WhatsApp